Статья
Случай амилоидоза в кардиологической практике
Представлены клинический случай амилоидоза и краткий обзор поражения сердечно-сосудистой системы, критериев постановки диагноза, принципов лечения при данном диагнозе.
1. Ronglih Liao, Jennifer E. Ward. Amyloid Cardiomyopathy: Disease on the Rise. Ward Circ Res 2017; 120:1865–1867. CIRC RES Journal ISSN: 0009-7330 (Print), 1524-4571 (Electronic).
2. Palladini G., Dispenzieri A., Gertz M.A. et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012; 30(36):4541– 4549. ISSN: 0732-183X (print) 1527-7755 (web)
3. Salinaro F., Meier-Ewert H.K., Miller E.J. et al. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging 2016; 2:12. DOI 10.1007/978-3-319-45237-1_4. ISBN 978-3-319-45236-4 (print) ISBN 978-3-319-45237-1 (online)
4. Schiano-Lomoriello V., Galderisi M., Mele D. et al. Longitudinal strain of left ventricular basal segments and E/e’ ratio differentiate primary cardiac amyloidosis at presentation from hypertensive hypertrophy: an automated function imaging study. Echocardiography 2016; Sep; 33(9):1335-1343. ISSN: 0742-2822 (print); 1540-8175 (online)
5. Gyanendra K. Sharma. Cardiac Amyloidosis. Mar 21, 2017. https://emedicine.medscape.com.
6. Damy T., Deux J.F., Moutereau S. et al. Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis. Amyloid 2013; 4:212-220. PMID: 23964755 DOI:10.3109/13506129.2013.825240
7. Ikeda S., Sekijima Y., Tojo K., Koyama J. Diagnostic value of abdominal wall fat pad biopsy in senile systemic amyloidosis. Amyloid 2011;18(4):211-215. PMID:23964755. DOI: 10.3109/13506129.2013.825240
8. Kuetting D.L., Homsi R., Sprinkart A.M. et al. Quantitative assessment of systolic and diastolic function in patients with LGE negative systemic amyloidosis using CMR. Int J Cardiol 2017 Apr 1; 232:336-341. ISSN: 0167-5273. PMID: 28153537. DOI: 10.1016/j.ijcard.2016.12.054.
9. Kwong R.Y., Heydari B., Abbasi S. et al. Characterization of cardiac amyloidosis by atrial late gadolinium enhancement using contrast-enhanced cardiac magnetic resonance imaging and correlation with left atrial conduit and contractile function. Am J Cardiol 2015 Aug 15; 116(4):622-629. PMID: 26076990 PMCID: PMC4769620 DOI: 10.1016/j.amjcard.2015.05.021. ISSN 0002-9149 (print) 1879-1913 (web)
10. Takashio S., Izumiya Y., Jinnin M. et al. Diagnostic and prognostic value of subcutaneous tissue biopsy in patients with cardiac amyloidosis. Am J Cardiol 2012 Nov 15; 110(10):1507-1511. PMID: 22863178. DOI: 10.1016/j.amjcard.2012.06.059.
11. Bodez D., Ternacle J., Guellich A. et al. Prognostic value of right ventricular systolic function in cardiac amyloidosis. Amyloid 2016 Sep; 23(3): 158-167. PMID: 23964755. DOI: 10.3109/13506129.2013.825240
12. Mohty D., Pibarot P., Dumesnil J.G. et al. Left atrial size is an independent predictor of overall survival in patients with primary systemic amyloidosis. Arch Cardiovasc Dis 2011 Dec; 104(12): 611-618. PMID: 22152513. DOI: 10.1016/j.acvd.2011.10.004.
13. Barison A., Aquaro G.D., Pugliese N.R. et al. Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging. J Intern Med 2015 May; 277(5):605-614. PMID: 25346163 DOI: 10.1111/joim.12324
14. Cytawa W., Teodorczyk J., Lass P. Nuclear imaging of amyloidosis. Pol J Radiol 2014 Jul 24; 79:222-227. PMID: 25071873. PMCID: PMC4111651. DOI: 10.12659/PJR.890147.
15. Sanchorawala V., Wright D.G., Seldin D.C. et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001 Oct; 28(7):637-642. PMID: 11704785 DOI: 10.1038/sj.bmt.1703200
16. Palladini G., Perfetti V., Obici L. et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004 Apr 15. 103(8):2936-2938. PMID: 15070667. DOI: 10.1182/blood-2003-08-2788
17. Palladini G., Sachchithanantham S., Milani P. et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 2015 Jul 30; 126(5):612-615. PMID: 25987656. DOI: 10.1182/blood-2015-01-620302
18. Sher T., Gertz M.A. Recent advances in the diagnosis and management of cardiac amyloidosis. Future Cardiol 2014 Jan; 10(1):131-146. PMID: 24344669. DOI: 10.2217/fca.13.85.
19. Sperry B.W., Ikram A., Hachamovitch R. et al. Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure. J Am Coll Cardiol 2016 Jun 28; 67(25):2941-2948. PMID: 27339491. DOI: 10.1016/j.jacc.2016.03.593
20. Wechalekar A.D., Goodman H.J., Lachmann H.J. et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007 Jan 15; 109(2):457-464. PMID: 16990593. DOI: 10.1182/blood-2006-07-035352
21. Grogan M., Gertz M., McCurdy A. et al. Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. World J Transplant 2016 Jun 24. 6(2):380-388. PMID: 27358783 PMCID: PMC4919742. DOI: 10.5500/wjt.v6.i2.380